(Q37696505)

22 August 2017

1 reference

title

The cardiac safety of trastuzumab in the treatment of breast cancer (English)

1 reference

22 August 2017

1 reference

1 reference

2

Hope S Rugo

1 reference

22 August 2017

A Jo Chien

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Drug Safety

22 August 2017

published in

1 reference

22 August 2017

volume

9

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

335-346

1 reference

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Targeting the function of the HER2 oncogene in human cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Requirement for neuregulin receptor erbB2 in neural and cardiac development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Essential roles of Her2/erbB2 in cardiac development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Neuregulin receptor ErbB2 localization at T-tubule in cardiac and skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Trastuzumab and cardiac dysfunction: update on preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Subcellular effects of adriamycin in the heart: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003627441

10.1517/14740331003627441

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference